World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
65128
World Ranking
6372
National Ranking
3396

E. David Crawford publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where E. David Crawford sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 716 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

E. David Crawford D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where E. David Crawford sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2003 - Member of the European Academy of Sciences

Overview

E. David Crawford is affiliated with the University of California, San Diego in the United States. Their research primarily focuses on medicine, encompassing various subfields such as pulmonary and respiratory medicine, oncology, cancer research, pathology and forensic medicine, and radiology, nuclear medicine, and imaging.

The scholar's main areas of study address critical topics including prostate cancer treatment and research, cancer related to lipids and metabolism, lymphoma diagnosis and treatment, CAR-T cell therapy research, cancer treatment and pharmacology, radiopharmaceutical chemistry and applications, as well as cancer immunotherapy and biomarkers.

Among recent papers authored or co-authored by E. David Crawford are the following:

  • "Current Frontline Treatment of Diffuse Large B-Cell Lymphoma," 2022, published in ONCOLOGY
  • "Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial," 2022, published in Journal of Clinical Oncology
  • "Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy," 2024, published in Journal of Clinical Oncology
  • "Real-world analyses of major adverse cardiovascular event risk by drug class after initiation of androgen deprivation therapy," 2022, published in Journal of Clinical Oncology
  • "LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL," 2022, published in The Journal of Urology

E. David Crawford frequently publishes in several scientific journals, notably:

  • Journal of Clinical Oncology
  • ONCOLOGY
  • The Journal of Urology
  • Urologic Oncology Seminars and Original Investigations

Their research collaborations have involved several frequent co-authors, including specialists associated with gastrointestinal cancer, Maha Hussain, Fred Saad, Karim Fizazi, and Cora N. Sternberg.

In recognition of their professional contributions, E. David Crawford has been a member of the European Academy of Sciences since 2003.

Best Publications

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Mortality Results from a Randomized Prostate-Cancer Screening Trial

    Gerald L. Andriole;E. David Crawford;Robert L. Grubb;Saundra S. Buys

  • Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

    Ian M. Thompson;Donna K. Pauler;Phyllis J. Goodman;Catherine M. Tangen

  • Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

    H. Barton Grossman;Ronald B. Natale;Catherine M. Tangen;V.O. Speights

  • Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

    Scott M. Lippman;Eric A. Klein;Eric A. Klein;Phyllis J. Goodman;M. Scott Lucia

  • The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

    John D. McConnell;Claus G. Roehrborn;Oliver M. Bautista;Gerald L. Andriole

  • Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

    Robert C. Flanigan;Sydney E. Salmon;Brent A. Blumenstein;Scott I. Bearman

  • Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

    Saundra S. Buys;Edward Partridge;Amanda Black;Christine C. Johnson

  • Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

    Gerald L. Andriole;E. David Crawford;Robert L. Grubb;Saundra S. Buys

  • Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

    Ian M. Thompson;Catherine M. Tangen;Jorge Paradelo;M. Scott Lucia

  • The national lung screening trial: Overview and study design

    Constantine A. Gatsonis;Denise R. Aberle;Christine D. Berg;William C. Black

  • Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy

    Robert E. Schoen;Paul F. Pinsky;Joel L. Weissfeld;Lance A. Yokochi

  • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

    Mario A. Eisenberger;Brent A. Blumenstein;E. David Crawford;Gary Miller

  • Multiple loci identified in a genome-wide association study of prostate cancer

    Gilles Thomas;Kevin B Jacobs;Meredith Yeager;Meredith Yeager;Peter Kraft

  • Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial

    Philip C Prorok;Gerald L Andriole;Robert S. Bresalier;Saundra S Buys

  • Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

    Ian M. Thompson;Catherine M. Tangen;Jorge Paradelo;M. Scott Lucia

  • Screening by Chest Radiograph and Lung Cancer Mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial

    Martin M. Oken;Willam G. Hocking;Paul A. Kvale;Gerald L. Andriole

  • Epidemiology of prostate cancer

    E.David Crawford

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

  • Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial

    M. Scott Lucia;Jonathan I. Epstein;Phyllis J. Goodman;Amy K. Darke

Frequent Co-Authors

Gerald L. Andriole
Gerald L. Andriole Washington University in St. Louis
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Catherine M. Tangen
Catherine M. Tangen Fred Hutchinson Cancer Research Center
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Paul F. Pinsky
Paul F. Pinsky National Institutes of Health
Maha Hussain
Maha Hussain Northwestern University
Robert L. Grubb
Robert L. Grubb Washington University in St. Louis
Meredith Yeager
Meredith Yeager Hood College
Stephen J. Chanock
Stephen J. Chanock National Institutes of Health
Fredrick R. Schumacher
Fredrick R. Schumacher Case Western Reserve University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those inspired to study Medicine in the USA but exploring alternative or supportive healthcare careers, many accessible online programs are available. Entry into healthcare is often possible through nursing, where students can find the cheapest rn to bsn program online to earn a bachelor’s degree and boost career prospects while managing educational costs.

If you hold a non-nursing bachelor's degree, accelerated pathways like online direct entry msn programs for non-nursing majors are designed to fast-track your nursing career. These options allow for a rapid transition into advanced nursing roles.

For those seeking an easier application process, consider schools on the list of easy nursing schools to get into. These institutions may offer greater acceptance rates, making them attractive for applicants wanting a smoother entry into nursing.

Not all medical careers require direct patient care. Consider programs for medical coding or billing, as medical billing and coding schools online with financial aid offer flexible, affordable training. These roles are essential for healthcare administration and offer strong job prospects.

Best Scientists Citing E. David Crawford

Trending Scientists

Recently Published Articles